Morgan, Robert D. http://orcid.org/0000-0003-0612-0954
Burghel, George J.
Flaum, Nicola
Bulman, Michael
Smith, Philip
Clamp, Andrew R.
Hasan, Jurjees
Mitchell, Claire L.
Salih, Zena
Woodward, Emma R.
Lalloo, Fiona http://orcid.org/0000-0002-0612-8377
Crosbie, Emma J. http://orcid.org/0000-0003-0284-8630
Edmondson, Richard J.
Wallace, Andrew J.
Jayson, Gordon C.
Evans, D. Gareth R.
Article History
Received: 22 September 2021
Revised: 4 February 2022
Accepted: 22 February 2022
First Online: 8 March 2022
Competing interests
: RDM, GJB, NF, MB, PS, JH, CLM, ZS, ERW, FL, EJC, RJE, AJW and DGRE declare no competing interests. GCJ declares research funding from AstraZeneca for investigator-led clinical trials. ARC declares research funding and advisory boards fees from AstraZeneca, and speaker and advisory board fees from Clovis Oncology.
: All women included in this study provided informed consent to undergo germline and tumour <i>BRCA1/2</i> testing. The germline <i>BRCA1/2</i> database is approved by North Manchester Research Ethics Committee (08/H1006/77). The Genetic Variants in Gynaecological Cancer database is approved by the Christie NHS Foundation Trust (59).
: Not applicable.